Before choosing a Freya Meds plan, ask for something more specific than a monthly price: a written explanation of what you will receive, who will prescribe it and what happens after the first charge. Freya’s advertising describes a convenient, supported weight-management service. But its homepage and treatment pages display different prices, while its terms exclude three states despite homepage messaging about patients across all 50 states. Those differences matter when deciding whether to begin an assessment or submit payment.
This documentary review examines Freya’s public pages consulted October 19, 2026, with practical questions for prospective US patients. Freya advertises semaglutide and tirzepatide, clinical review, home delivery and continuing support. Its legal role, however, is an administrative and technology platform supporting independent clinical entities. The useful task is to separate what the company explicitly offers from what still needs confirmation—not to assume that every advertised feature applies to every plan or that completing an intake guarantees a prescription.
At a glance
- Different published prices
- The homepage lists semaglutide starting as low as $150 per month and tirzepatide at $249; treatment pages show higher monthly and quarterly-billed rates.
- State restrictions
- The terms exclude Alabama, Mississippi and West Virginia and limit services to people located in the United States.Sources: [6]
- Independent clinical care
- Freya describes itself as nonclinical; the patient-provider relationship and prescribing decisions belong to an independent licensed healthcare provider.Sources: [6]
- Direct payment
- The terms state that Freya and affiliated clinical entities do not accept commercial insurance or participate in Medicare or Medicaid.Sources: [6]
Can you actually enroll where you live?
Start with location rather than medication selection. Freya’s homepage claims more than 450,000 patients across all 50 US states. Its terms, however, explicitly say services are unavailable in Alabama, Mississippi and West Virginia and that residents of those states cannot complete checkout. A statement about the geographic reach of a patient population is not reliable confirmation of present enrollment availability. For someone in an excluded state, the restrictive terms are the material information to resolve before proceeding.
The terms also limit the service to people located in the United States and describe an intended population age 18 or older. These are separate conditions: adulthood alone does not establish access, and a supported state does not establish clinical eligibility. Ask whether your location is supported for both consultation and prescription fulfillment. The public documentation does not resolve how the service handles a patient who travels or changes residence during treatment.
The next question is who will be responsible for care in your state. Freya’s terms identify FREYA MEDS International Inc. and affiliates, although the document heading uses FREYA MEDS INC. They describe independent, state-licensed professional corporations without naming those entities in the consulted material. Request the clinical entity’s name and your practitioner’s credentials before relying on broad platform branding. This is a request for clarity, not a finding that any practitioner lacks a license.
What will the assessment decide—and when does payment begin?
Freya describes its opening step as a confidential assessment covering health, goals and lifestyle, with no commitment required. Its homepage says a licensed healthcare provider reviews medical history, current medications, weight-loss goals and the overall medical profile. It explicitly states that not everyone qualifies. Before entering payment information, ask which steps remain commitment-free, when a charge is collected and what happens financially if the clinician declines to prescribe. Those payment boundaries are not established by the assessment’s no-commitment language.
The semaglutide page addresses adults who have struggled to lose weight through diet and exercise and describes a BMI of 27 or above as a preferred profile. That marketing description is not a complete eligibility protocol. NIDDK explains that medication selection also involves health conditions, other medicines, benefits, side effects and costs. Bring those topics to the consultation rather than treating a website’s BMI statement as confirmation that a particular medicine is appropriate for you.
Freya advertises same-day prescription review and confirmation by a US-licensed doctor after selecting an option. Treat that as an advertised review timeline, not guaranteed approval, a delivery date or proof that every interaction is with a physician. The terms assign clinical decisions to an independent licensed healthcare provider. Our consultation question guide can help organize questions about the appointment format, the clinician’s role and how a decision will be communicated.
Which published price would apply to your order?
Freya has more than one public price presentation. The homepage advertises semaglutide starting as low as $150 per month and tirzepatide starting as low as $249 per month, without explaining the conditions needed to obtain those minimums. The individual treatment pages instead show monthly plans and lower monthly-equivalent rates billed and delivered quarterly. None of these figures should disappear into a vague statement that pricing varies: each is documented, but their relationship is unresolved.
The table separates the published offers without assuming they describe identical products or enrollment terms. The consulted pages do not establish the exact formulation, route or presentation attached to each price. Ask Freya to identify the medicine and plan connected to your quote, the amount collected today, the next charge and the billing interval. A quarterly billing label signals a different payment arrangement from a monthly plan; it does not, by itself, establish a minimum commitment or an exact supply quantity.
The homepage also displayed a promotion of up to $272 off three-month plans at checkout, ending October 31 without a year. Its applicability and current validity require confirmation. Do not assume the lowest homepage price already includes that promotion or that it is an introductory rate; neither condition is established. Use our questions beyond the monthly price to request an itemized quote rather than calculating a deal from disconnected page fragments.
| Page and medicine | Advertised price | Condition or unresolved detail |
|---|---|---|
| Homepage: semaglutide | Starting as low as $150 per month | Conditions for the minimum are not explained. |
| Homepage: tirzepatide | Starting as low as $249 per month | Conditions for the minimum are not explained. |
| Semaglutide treatment page | $250 per month; $297 per month for monthly plans | $250 rate is billed quarterly and delivered quarterly. |
| Tirzepatide treatment page | $332 per month; $390 per month for monthly plans | $332 rate is billed quarterly and delivered quarterly. |
| Homepage promotion | Up to $272 off three-month plans at checkout | Ends October 31; year and current applicability are unconfirmed. |
What does the payment include, and what could be separate?
Freya’s homepage says the price usually includes medication, syringes, shipping and access to medical consultations and support. The word “usually” matters: it is not an unconditional promise that every expense is bundled. The semaglutide treatment table advertises medication, unlimited doctor consultations, monthly group calls and a one-on-one dietitian consultation. Ask which of these benefits appear in your actual plan, how the dietitian appointment is arranged and whether any advertised service has scheduling or usage conditions.
Freya also states that payment covers the full monthly treatment plan rather than a particular vial, and that the cost stays the same regardless of the clinician’s individual dose determination. That is a provider billing claim, not a description of the quantity shipped. Meanwhile, the terms make patients responsible for associated healthcare-provider, laboratory and pharmacy charges. Required testing and its possible cost remain unclear. Request confirmation of any separately billed labs, consultations or pharmacy services before assuming an all-inclusive total.
The terms describe cash-pay service: Freya and affiliated clinical entities do not accept commercial insurance, are not in-network and do not participate in Medicare or Medicaid. That describes the payment model, not an explicit prohibition on enrollment by every person who has such coverage. Payments run through third-party processors. Ask what receipt or itemization is available, but do not assume reimbursement, insurance billing or a particular tax treatment from the fact that a service is medical.
What exactly would the pharmacy dispense?
Freya advertises semaglutide and tirzepatide, but the consulted documentation does not establish the exact formulation, presentation, administration route or compounded status of every product actually dispensed. Mentions of syringes and vials do not settle all those questions. Nor do comparisons with ingredients in familiar brands establish that patients receive those branded products. Before comparing the offer with another program, request the prescription product’s full identity and ask whether it is FDA approved or compounded.
The terms contemplate compounded medications when an independent clinician considers them appropriate. They explain that these preparations are not FDA reviewed or approved for safety, effectiveness or manufacturing quality, and disclaim guarantees about their safety, efficacy, purity and quality. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence; it also does not support treating a compounded preparation as an approved product.
Ask who will dispense the prescription and who can answer product-specific questions. The consulted material does not name the dispensing pharmacies. The terms allow selection of a partner pharmacy and, when that option is offered during service use, a pharmacy of the patient’s choice. That conditional language does not promise unrestricted pharmacy choice at every step. Our medication identification questions can help distinguish the ingredient name, actual preparation and dispensing pharmacy before payment.
Who answers between prescriptions?
Freya’s treatment advertising promises continuity with the same doctor, weekly check-ins and adjustments. Its homepage lists unlimited clinician and care-team access, plus monthly expert sessions with questions and answers. Another page describes messaging access to the practitioner who knows the case. These are meaningful features to clarify because they describe different kinds of contact. Ask whether weekly check-ins are scheduled, how practitioner messaging works and which concerns go to administrative staff rather than a licensed clinician.
Freya also advertises nutrition plans, meal guidance, lifestyle coaching, habit-building tools and dashboard-based progress tracking. Those resources suggest support beyond medication delivery, but the consulted pages do not fully explain their format or frequency. A monthly group call is not the same service as an individual dietitian consultation. Ask what is personalized, who provides each service and how to book it. The documented feature list does not establish guaranteed response times or availability of care in Spanish.
For something that does not feel right during treatment, the semaglutide page directs patients to contact their practitioner, who can change the approach based on the response. Freya’s terms explicitly exclude emergency care and direct patients with a medical emergency to call 911 and seek immediate treatment. Published contact hours should therefore not be interpreted as round-the-clock clinical coverage. Before enrollment, identify the clinical contact route, the after-hours process and how routine questions differ from urgent concerns.
What happens if delivery does not go as expected?
The homepage advertises free, discreet shipping and monthly medication delivery; quarterly treatment plans separately say delivery is quarterly. Treatment pages also promote “Fast 3 Day Shipping.” That phrase does not explain when the clock starts or whether it describes dispatch, transit or arrival. Same-day clinical review is a separate claim. Ask for the expected sequence from payment through approval, pharmacy processing and arrival, including how tracking is provided and who handles a delayed or missing package.
The tirzepatide page describes medicine delivered properly stored and ready to use, but the consulted material does not detail packaging or the cold chain. For an injectable GLP-1 product that arrives warm or with insufficient refrigeration, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. Establish the contact and replacement process beforehand rather than assuming that free shipping includes a particular replacement policy. The public documentation does not resolve replacement charges or turnaround.
One unusually concrete shipping disclosure deserves attention: Freya’s terms state that medications fulfilled through its pharmacy network will not arrive in child-resistant packaging and must be kept out of children’s reach. That warning applies to the network channel described in the terms, not necessarily every possible outside pharmacy. Ask what packaging your order uses and what storage instructions accompany it. Our delivery problem questions provide a framework for discussing these responsibilities without treating a shipping slogan as a delivery guarantee.
What should be settled before the next charge—or departure?
Freya advertises month-to-month care without membership fees or lock-in, while its treatment pages offer quarterly billing and delivery and say patients can cancel anytime. These statements do not explain the mechanics of leaving. The consulted documentation does not establish automatic-renewal rules, a cancellation deadline or procedure, refund eligibility, or what happens to prepaid quarterly amounts. Ask for those terms in writing before choosing a billing interval. Cancellation of future service does not itself establish a right to recover an earlier payment.
There are useful published contact paths. The privacy policy lists contact@freyameds.com, a mailing address at 30 N Gould St Ste R, Sheridan, Wyoming 82801, and hours Monday through Sunday, 8 a.m. to 8 p.m. Eastern. Those hours do not establish a guaranteed response time. For transferring a telehealth record, the terms direct patients to doctor@freyameds.com with consent and the receiving provider’s name, address and phone number. Record transfer is distinct from cancelling billing.
The privacy policy also allows requests for data access, correction or deletion and restrictions on certain processing, subject to applicable law, through the general contact email. Deletion should not be assumed to erase every clinical record or terminate a subscription. Finally, the terms include individual binding arbitration, subject to described exceptions. Read those provisions as part of enrollment preparation; they concern dispute handling and do not establish the language options available for clinical appointments.
Questions & answers
Can I count on Freya’s $150 semaglutide price?
Not without a quote confirming its conditions. The homepage says semaglutide starts as low as $150 per month, but the treatment page lists $250 per month billed and delivered quarterly, or $297 for monthly plans. Ask which product and billing option qualify for the homepage minimum and whether the quote applies beyond the first payment. The consulted pages do not reconcile these figures.
Does Freya serve all 50 states?
The homepage’s claim about patients across 50 states should not be read as current nationwide availability. The terms specifically exclude Alabama, Mississippi and West Virginia and say their residents cannot complete checkout. They also limit services to people located in the United States. Confirm present eligibility for your location before sharing payment details, especially if another page suggests broader coverage.
Is Freya itself my medical provider?
According to its terms, Freya is a nonclinical administrative and technology service provider. Your clinical relationship is with an independent licensed healthcare provider practicing through an affiliated professional corporation. That provider is responsible for diagnosis, treatment and prescribing. Ask for the clinical entity and practitioner names so you know who handles medical questions, while separately identifying who handles payments and platform support.
Will I receive branded medicine or a compounded preparation?
The consulted documentation does not identify every dispensed product precisely enough to answer that for an individual order. Freya’s terms contemplate compounded medications, but that does not prove every prescription is compounded. Ask for the exact product, formulation, route, presentation and pharmacy. FDA approval belongs to a specific product, not to the platform, and ingredient comparisons with well-known brands do not establish that those brands are supplied.
Does cancelling return money already paid for a quarterly plan?
The public documentation does not establish that. Freya advertises cancellation at any time, but the consulted material does not explain refunds of prepaid quarterly charges, the cancellation procedure or notice deadlines. Ask separately when future billing stops and whether any earlier payment is refundable. A statement that there is no lock-in does not answer what happens to money collected for a quarterly-billed plan.
How can I move my Freya telehealth record to another provider?
The terms say to email doctor@freyameds.com with your consent and the receiving healthcare provider’s name, address and phone number. Ask how the transfer will be confirmed and whether anything else is required. For general privacy requests, the policy lists contact@freyameds.com. Neither requesting records nor asking about data deletion should be assumed to cancel a treatment plan or stop future charges.
Our assessment
Freya documents a potentially useful combination of online clinical review, medication delivery, practitioner messaging, nutrition resources and continuing contact. Its cash-pay model and independent-clinician structure are also expressly described. The main obstacle to a well-informed enrollment decision is not a complete absence of information, but unresolved differences and missing operational detail: competing price presentations, restricted states, uncertain product identity and incomplete cancellation and refund rules. Before paying, obtain a written quote identifying the medicine, dispensing pharmacy, included services, billing interval and exit terms. Confirm who handles clinical questions and delivery problems. Those answers would make the offer meaningfully easier to evaluate; the advertised starting price alone does not.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Freya / Freya Meds — official website ↗
- Freya / Freya Meds — how it works ↗
- Freya / Freya Meds — privacy policy ↗
- Freya / Freya Meds — terms and conditions ↗
- Freya / Freya Meds — semaglutide ↗
- Freya / Freya Meds — tirzepatide ↗